MD Anderson has numerous presentations throughout the 2025 ASH Annual Meeting. All times listed in Eastern Time.
MD Anderson has numerous presentations throughout the 2025 ASH Annual Meeting. All times listed in Eastern Time.
Friday, December 5
Scientific Workshops
Disease Models and Mechanisms: Bridging the Gap
Orange County Convention Center W307
3:07每3:12&紳莉莽梯;梯.鳥.
Speaker:
A New Horizon in Hematology: Novel Strategies for Reversing Aging
Orange County Convention Center W312
5:18每5:28 p.m.
Speaker: Daisy Diaz-Rohena, Ph.D.
5:48每5:57 p.m.
Saturday, December 6
Oral Abstract Sessions
617. Acute Myeloid Leukemias: Commercially Available Therapies: Frontline treatment with intensive or lower-intensity regimens
Orange County Convention Center Valencia Room W415A
Presentation ID 45:
10每10:15 a.m.
Speaker: Roberta Santos Azevedo, M.D.
Presentation ID 47:
10:30每10:45 a.m.
Speaker:
642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Treatment of CLL in Relapse and in Richter Transformation
Orange County Convention Center W224ABEF
Presentation ID 89:
10:30每10:45 a.m.
Speaker:
907. Outcomes Research: Plasma Cell Disorders: Real-world Outcomes of Targeted Immunotherapies in Patients with Multiple Myeloma
Orange County Convention Center West Hall E2
Presentation ID 137:
10:30每10:45 a.m.
Speaker:
624. Hodgkin Lymphomas: Clinical and Epidemiological: Improving Outcomes in Hodgkin Lymphoma Utilizing Targeted Therapeutics, Prognostic Modeling, and Predictive Tools
Orange County Convention Center Tangerine Ballroom F2
Presentation ID 153:
12:30每12:45 p.m.
Speaker:
701. Experimental Transplantation: Basic and Translational: GVHD, thymopoiesis and the host regenerative response
Orange County Convention Center Chapin Theater (W320)
Presentation ID 162:
1:15每1:30 p.m.
Speaker: Eiko Hayase, M.D.
721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Optimizing Outcomes in Pediatric, Adolescent and Young Adult Patients
Orange County Convention Center W331
Presentation ID 168:
1:15每1:30 p.m.
Speaker:
637. Myelodysplastic Syndromes: Clinical and Epidemiological: Treatment Advances in Higher Risk Myelodysplastic Syndromes
Orange County Convention Center Valencia Room W415BC
Presentation ID 235:
2每2:15 p.m.
Speaker:
Presentation ID 237:
2:30每2:45 p.m.
Speaker:
301. Platelets and Megakaryocytes: Basic and Translational: Novel mechanisms of platelet signaling
Orange County Convention Center W304ABCD
Presentation ID 196:
2:45每3 p.m.
Speaker:
655. Multiple Myeloma: Cellular Therapies: Clinical Trial Advances in CAR T-Cell Therapy for Multiple Myeloma
Orange County Convention Center West Hall E1
Presentation ID 256:
2:45每3 p.m.
Speaker:
618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Redefining AML: Genetic, Phenotypic and Response-Based Insights
Orange County Convention Center W414AB
Presentation ID 222:
3:15每3:30 p.m.
Speaker: Yi June Kim
802. Chemical Biology and Experimental Therapeutics: Novel therapeutics in hematologic malignancies?
Orange County Convention Center W331
Presentation ID 388:
4:45每5:00 p.m.
Speaker:
605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Beyond Genomic Resistance: epigenetics, metabolism and more
Orange County Convention Center W230
Presentation ID 330:
5:15每5:30 p.m.
Speaker:
721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Optimizing Outcomes in Adult and Elderly Patients
Orange County Convention Center Sunburst Room (W340)
Presentation ID 378:
5:15每5:30 p.m.
Speaker:
802. Chemical Biology and Experimental Therapeutics: Novel therapeutics in hematologic malignancies?
Orange County Convention Center W331
Presentation ID 390:
5:15每5:30 p.m.
Speaker:
Education Program
Complementopathies: Modern Diagnosis and Management
Hyatt Regency Ballroom S
2每2:20 p.m.
Speaker: Vahid Afshar-Kharghan, M.D.
Blood Journals Studio
Orange County Convention Center West Halls B3每B4
2每2:45 p.m.
Speaker:
Scientific Program
Innovative Models of Lymphoma
Orange County Convention Center West Hall E2
2:20每2:40 p.m.
Speaker:
Special-Interest Sessions
Joint Session: Advancing Hematology Through Artificial Intelligence
Hyatt Regency Ballroom S
4:40每5:00 p.m.
Speaker:
Hematology Inclusion Pathway (HIP) Oral Presentations - Malignant Hematology I
Hyatt Florida Ballroom A
6:30每8:00 p.m.
Speaker:
Sunday, December 7
Oral Abstract Sessions
637. Myelodysplastic Syndromes: Clinical and Epidemiological: Moving the Needle Through Novel Approaches in MDS and CMML
Orange County Convention Center Valencia Room W415D
Presentation ID 487:
9:30每9:45 a.m.
Speaker:
Presentation ID 489:
9:45每10 a.m.
Speaker:
Presentation ID 491:
10:15每10:30 a.m.
Speaker:
627. Aggressive Lymphomas: Targeted and Pharmacologic Therapies - Targeted Agents and Chemotherapy Intensification in Aggressive B-cell Lymphomas
Orange County Convention Center Tangerine Ballroom F3-4
Presentation ID 477:
10每10:15 a.m.
Speaker:
623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological - Immunotherapies for Follicular Lymphoma
Orange County Convention Center West Hall D2
Presentation ID 467:
10:30每10:45 a.m.
Speaker:
612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Optimizing risk stratification, treatment, and diagnostics of ALL in the immunotherapy era
Orange County Convention Center W224ABEF
Presentation ID 549:
12:30每12:45 p.m.
Speaker: Roberta Santos Azevedo, M.D.
908. Outcomes Research: Myeloid Malignancies: Treatment and Outcomes in the Real-World
Orange County Convention Center W414CD
Presentation ID 6041:
12:45每1 p.m.
Speaker: Vaishali Gautam
723. Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence: Predicting and elucidating relapse
Orange County Convention Center W331
Presentation ID 592:
12:45每1 p.m.
Speaker:
612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Optimizing risk stratification, treatment, and diagnostics of ALL in the immunotherapy era
Orange County Convention Center W224ABEF
Presentation ID 551:
1每1:15 p.m.
Speaker: Manuel Maroun, M.D.
654. Multiple Myeloma: Pharmacologic Therapies: Bi, Tri and Beyond: Innovations in Bispecific and Trispecific Antibodies for Multiple Myeloma
Orange County Convention Center West Hall E1
Presentation ID 697:
4:30每4:45 p.m.
Speaker:
636. Myelodysplastic Syndromes: Basic and Translational: Mechanisms of MDS Initiation and Progression
Orange County Convention Center Valencia Room W415A
Presentation ID 6741:
4:45每5 p.m.
Speaker: Yu-Hsiang Chen, Ph.D.
907. Outcomes Research: Plasma Cell Disorders: Therapeutic Toxicity in Multiple Myeloma: Real-World Evidence and Clinical Approaches
Orange County Convention Center West Hall D1
Presentation ID 716:
4:45每5 p.m.
Speaker: Muhammad Bilal Abid, M.D.
642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Frontline Treatment Strategies for CLL
Orange County Convention Center W224ABEF
Presentation ID 680:
4:45每5 p.m.
Speaker:
616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Immunotherapy and chemotherapy combinations in AML
Orange County Convention Center Chapin Theater (W320)
Presentation ID 651:
5每5:15 p.m.
Speaker:
642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Frontline Treatment Strategies for CLL
Orange County Convention Center W224ABEF
Presentation ID 681:
5每5:15 p.m.
Speaker:
623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological - Novel Treatments for and Insights into Mantle Cell Lymphoma
Orange County Convention Center Tangerine Ballroom F2
Presentation ID 663:
5每5:15 p.m.
Speaker:
623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological - Novel Treatments for and Insights into Mantle Cell Lymphoma
Orange County Convention Center Tangerine Ballroom F2
Presentation ID 665:
5:30每5:45 p.m.
Speaker:
628. Aggressive Lymphomas: Cellular Therapies: Novel Cellular Therapeutic Strategies for Aggressive Lymphomas
Orange County Convention Center Tangerine Ballroom F3-4
Presentation ID 670:
5:15每5:30 p.m.
Speaker:
908. Outcomes Research: Myeloid Malignancies: Real-World Experiences
Orange County Convention Center W414CD
Presentation ID 725:
5:30每5:45 p.m.
Speaker:
Scientific Spotlight Session
Strategies to Reduce Immune Rejection of Off-the-Shelf Cell Therapies
Orange County Convention Center Sunburst Room (W340)
4:30每5:45 p.m.
Co-Chair and Speaker:
Monday, December 8
Oral Abstract Sessions
702. CAR-T Cell Therapies: Basic and Translational: Mechanisms of CAR-T cell toxicity and persistence
Orange County Convention Center W331
Presentation ID 806:
10:45每11 a.m.
Speaker:
907. Outcomes Research: Plasma Cell Disorders: Special Populations in Plasma Cell Disorders: Efficacy and Safety of Therapies in Real-World Settings
Orange County Convention Center West Hall E2
Presentation ID 823:
10:30每10:45 a.m.
Speaker:
Presentation ID 824:
10:45每11 a.m.
Speaker:
616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Menin inhibitors and FLT3 inhibitors in AML
Orange County Convention Center Chapin Theater (W320)
Presentation ID 763:
10:30每10:45 a.m.
Speaker:
612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Predicting and improving outcomes in common and rare subgroups of pediatric ALL
Orange County Convention Center W224CDGH
Presentation ID 759:
11每11:15 a.m.
Speaker: Sankalp Arora, M.B.B.S.
637. Myelodysplastic Syndromes: Clinical and Epidemiological: Treatment Advances in Lower risk Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms
Orange County Convention Center Valencia Room W415A
Presentation ID 790:
11:15每11:30 a.m.
Speaker:
626. Aggressive Lymphomas: Epidemiological Excluding Prospective Clinical Trials: Real-World data on clinical predictors of outcome
Orange County Convention Center Tangerine Ballroom F3-4
Presentation ID 895:
2:45每4 p.m.
Speaker:
632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Therapeutic agents to enhance patient outcomes
Orange County Convention Center Chapin Theater (W320)
Presentation ID 901:
2:45每3 p.m.
Speaker:
722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: GVHD Prevention: Post-transplant cyclophosphamide and beyond
Orange County Convention Center W331
Presentation ID 932:
3每3:15 p.m.
Speaker:
623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas:?Clinical and Epidemiological: Single Agent and Combination therapy for MCL
Orange County Convention Center Tangerine Ballroom F1
Presentation ID 885:
3:15每3:30 p.m.
Speaker:
617. Acute Myeloid Leukemias: Commercially Available Therapies: Combination regimens and targeted therapies
Orange County Convention Center Chapin Theater (W320)
Presentation ID 997:
4:30每4:45 p.m.
Speaker: Roberta Santos Azevedo, M.D.
Posters
Saturday, December 6
Poster Abstract Session
Orange County Convention Center West Halls B3每B4
5:30每7:30 p.m.
114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Poster I
Presentation ID 117:
Presenter: Kaung Htet Hla Win, M.B.
Presentation ID 1196:
Presenter: Kaung Htet Hla Win, M.B.
401. Blood Transfusion: Poster I
Presentation ID 1368:
Presenter: Hila Shaim, M.D., Ph.D.
509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: Poster I
Presentation ID 1435:
Presenter: Leticia Campoverde, M.D.
604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster I
Presentation ID 1496:
Presenter: Saurabh Kumar Gupta, Ph.D.
Presentation ID 1497:
Presenter:
Presentation ID 1500:
Presenter:
Presentation ID 1510:
Presenter:
Presentation ID 1513:
Presenter: Anna Sergeeva, Ph.D.
612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Poster I
Presentation ID 1558:
Presenter: Trevor Jamison, M.D.
Presentation ID 1556:
Presenter: Hannah Goulart, M.D.
Presentation ID 1544:
Presenter: Grace Park, Pharm.D.
613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Poster I
Presentation ID 1566:
Presenter: Hannah Goulart, M.D.
Presentation ID 1567:
Presenter: Hannah Goulart, M.D.
Presentation ID 1571:
Presenter: Hannah Goulart, M.D.
Presentation ID 1573:
Presenter:
Presentation ID 1578:
Presenter: Koji Sasaki, M.D., Ph.D.
614. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Measurable Residual Disease in Diagnosis and Prognosis: Poster I
Presentation ID 1593:
Presenter: Samanta Catueno, M.D.
615. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster I
Presentation ID 1620:
Presenter: Michelle Nwachukwu, D.O.
Presentation ID 1630:
Presenter: Roberta Santos Azevedo, M.D.
Presentation ID 1634:
Presenter: Roberta Santos Azevedo, M.D.
616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Poster I
Presentation ID 1641:
Presenter:
Presentation ID 1642:
Presenter:
Presentation ID 1646:
Presenter:
Presentation ID 1652:
Presenter:
Presentation ID 1653:
Presenter:
617. Acute Myeloid Leukemias: Commercially Available Therapies: Poster I
Presentation ID 1678:
Presenter: Hannah Goulart, M.D.
Presentation ID 1688:
Presenter: Farah Al Haj, M.D.
618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Poster I
Presentation ID 1726:
Presenter: Roberta Santos Azevedo, M.D.
Presentation ID 1724:
Presenter:
621. Lymphomas: Translational 每 Molecular and Genetic: Poster I
Presentation ID 1764:
Presenter: Fangfang Yan, Ph.D.
Presentation ID 1765:
Presenter: Fangfang Yan, Ph.D.
622. Lymphomas: Translational - Non-Genetic: Poster I
Presentation ID 1785:
Presenter: Vivian Jiang, Ph.D.
623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster I
Presentation ID 1829:
Presenter:
Presentation ID 1837:
Presenter:
624. Hodgkin Lymphomas: Clinical and Epidemiological: Poster I
Presentation ID 1844:
Presenter:
625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: Poster I
Presentation ID 1869:
Presenter:
628. Aggressive Lymphomas: Cellular Therapies: Poster I
Presentation ID 1931:
Presenter:
629. Aggressive Lymphomas, Immunotherapy including Bispecific Antibodies: Poster I
Presentation ID 1967:
Presenter: Kunhwa Kim, M.D.
631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster I
Presentation ID 1983:
Presenter:
632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster I
Presentation ID 2010:
Presenter: Mina Abdelmalek, M.D.
634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster I
Presentation ID 2037:
Presenter: Hannah Goulart, M.D.
637. Myelodysplastic Syndromes: Clinical and Epidemiological: Poster I
Presentation ID 2075:
Presenter:
642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster I
Presentation ID 2115:
Presenter:
701. Experimental Transplantation: Basic and Translational: Poster I
Presentation ID 2306:
Presenter:
702. CAR-T Cell Therapies: Basic and Translational: Poster I
Presentation ID 2337:
Presenter: Cuong Le, Ph.D.
732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster I
Presentation ID 2511:
Presenter:
Presentation ID 2515:
Presenter:
903. Health Services and Quality Improvement: Myeloid Malignancies: Poster I
Presentation ID 2648:
Presenter:
906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Poster I
Presentation ID 2713:
Presenter: Zachary Hunzeker, M.D.
Presentation ID 2716:
Presenter: Bryan Valcarcel, M.D.
Presentation ID 2719:
Presenter: Rahul Shah, M.D.
908. Outcomes Research: Myeloid Malignancies: Poster I
Presentation ID 2826:
Presenter:
Sunday, December 7
Poster Abstract Session
Orange County Convention Center West Halls B3每B4
6每8 p.m.
102. Iron Homeostasis and Biology in Physiological and Pathological Conditions: Poster II
Presentation ID 2906:
Presenter: Reeja Raj
201. Granulocytes, Monocytes, and Macrophages: Poster II
Presentation ID 2980:
Presenter: Mitchell Boshkos, D.O.
323. Disorders of Coagulation, Bleeding, or Fibrinolysis, Excluding Congenital Hemophilias: Clinical and Epidemiological: Poster II
Presentation ID 3091:
Presenter: Sidra Naz, M.D.
332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Poster II
Presentation ID 3131:
Presenter: Jhoan Sebastian Gonzalez Diaz, M.D.
503. Clonal Hematopoiesis, Aging, and Inflammation: Poster II
Presentation ID 3160
Presenter:
508. Bone Marrow Failure: Acquired: Poster II
Presentation ID 3206:
Presenter:
604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster II
Presentation ID 3266:
Presenter:
Presentation ID 3276:
Presenter:
605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster II
Presentation ID 3314 :
Presenter:
612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Poster II
Presentation ID 3326:
Presenter:
613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Poster II
Presentation ID 3348:
Presenter: Hannah Goulart, M.D.
Presentation ID 3350:
Presenter: Hannah Goulart, M.D.
614. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Measurable Residual Disease in Diagnosis and Prognosis: Poster II
Presentation ID 3370:
Presenter:
615. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster II
Presentation ID 3397:
Presenter: Sankalp Arora, M.B.B.S.
Presentation ID 3399:
Presenter: Jennifer Marvin-Peek, M.D.
616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Poster II
Presentation ID 3429:
Presenter:
617. Acute Myeloid Leukemias: Commercially Available Therapies: Poster II
Presentation ID 3459:
Presenter: Niranjan Khaire, M.B.B.S., M.D., D.M.
Presentation ID 3461:
Presenter:
618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Poster II
Presentation ID 3503:
Presenter: Sara Nofal, M.D., Ph.D.
621. Lymphomas: Translational 每 Molecular and Genetic: Poster II
Presentation ID 3545:
Presenter:
623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster II
Presentation ID 3571:
Presenter:
625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: Poster II
Presentation ID 3653:
Presenter: Roberta Santos Azevedo, M.D.
628. Aggressive Lymphomas: Cellular Therapies: Poster II
Presentation ID 3717:
Presenter:
631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster II
Presentation ID 3758:
Presenter: Wei Xiao, Ph.D.
634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster II
Presentation ID 3795:
Presenter:
Presentation ID 3803:
Presenter:
625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: Poster II
Presentation ID 3636:
Presenter: Bryan Valcarcel, M.D.
627. Aggressive Lymphomas: Targeted and Pharmacologic Therapies: Poster II
Presentation ID 3691:
Presenter: Eduardo Edelman Saul, M.D.
628. Aggressive Lymphomas: Cellular Therapies: Poster II
Presentation ID 3709:
Presenter: Jinsheng Weng, M.D., Ph.D.
634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster II
Presentation ID 3810:
Presenter:
636. Myelodysplastic Syndromes: Basic and Translational: Poster II
Presentation ID 3832:
Presenter:
Presentation ID 3839:
Presenter: Hui Yang, Ph.D.
637. Myelodysplastic Syndromes: Clinical and Epidemiological: Poster II
Presentation ID 3848:
Presenter:
Presentation ID 3849:
Presenter:
Presentation ID 3874:
Presenter:
Presentation ID 3867:
Presenter:
907. Outcomes Research: Plasma Cell Disorders: Poster II
Presentation ID 4575:
Presenter: Christen Dillard, M.D.
908. Outcomes Research: Myeloid Malignancies: Poster II
Presentation ID 4613:
Presenter:
Presentation ID 4634:
Presenter:
642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster II
Presentation ID 3892:
Presenter:
653. Multiple Myeloma: Clinical and Epidemiological: Poster II
Presentation ID 3987:
Presenter:
637. Myelodysplastic Syndromes: Clinical and Epidemiological: Poster II
Presentation ID 3857:
Presenter: Roberta Santos Azevedo, M.D.
703. Cellular Immunotherapies other than CAR-T Cells: Poster II
Presentation ID 4137:
Presenter: Sandeep Singh, Ph.D.
704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster II
Presentation ID 4148:
Presenter:
903. Health Services and Quality Improvement: Myeloid Malignancies: Poster II
Presentation ID 4435:
Presenter: Ummul Asfeen, D.O.
905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Poster II
Presentation ID 4470:
Presenter: Yin Mon Myat, M.B., B.Ch.
906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Poster II
Presentation ID 4482:
Presenter:
908. Outcomes Research: Myeloid Malignancies: Poster II
Presentation ID 4605:
Presenter:
Monday, December 8
Poster Abstract Session
Orange County Convention Center West Halls B3每B4
6每8 p.m.
332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Poster III
Presentation ID 4909:
Presenter: Elyse Cortez
503. Clonal Hematopoiesis, Aging, and Inflammation: Poster III
Presentation ID 4952:
Presenter: Shelley Herbrich, Ph.D.
506. Bone Marrow Microenvironment: Poster III
Presentation ID 4957: iPSC-derived mesenchymal stromal cells (iMSC) provide superior support for hematopoietic reconstitution compared to BM-MSCs
Presenter: Olayinka Okeleji, M.D.
604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster III
Presentation ID 5050:
Presenter: Kazuharu Kamachi, M.D., Ph.D.
Presentation ID 5053:
Presenter:
Presentation ID 5057:
Presenter: Liang Zhang, Ph.D.
Presentation ID 5060:
Presenter:
613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Poster III
Presentation ID 5117:
Presenter:
Presentation ID 5131:
Presenter: Hannah Goulart, M.D.
614. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Measurable Residual Disease in Diagnosis and Prognosis: Poster III
Presentation ID 5150:
Presenter: Niranjan Khaire, M.B.B.S., M.D., D.M.
Presentation ID 5151:
Presenter:
615. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster III
Presentation ID 5156:
Presenter: Reeja Raj, D.O.
Presentation ID 5167:
Presenter: Sankalp Arora, M.B.B.S.
Presentation ID 5179:
Presenter: William Marrero, M.D.
616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Poster III
Presentation ID 5194:
Presenter:
Presentation ID 5195:
Presenter:
Presentation ID 5204:
Presenter: Hannah Goulart, M.D.
617. Acute Myeloid Leukemias: Commercially Available Therapies: Poster III
Presentation ID 5226:
Presenter: Sankalp Arora, M.B.B.S.
623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster III
Presentation ID 5369:
Presenter:
Presentation ID 5384:
Presenter: Tony Zhuang, M.D.
Presentation ID 5393:
Presenter:
625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: Poster III
Presentation ID 5422:
Presenter: Eduardo Edelman Saul, M.D.
Presentation ID 5432:
Presenter:
Presentation ID 5434:
Presenter: Eduardo Edelman Saul, M.D.
628. Aggressive Lymphomas: Cellular Therapies: Poster III
Presentation ID 5485:
Presenter:
Presentation ID 5500:
Presenter: Muhammad Bilal Abid, M.D.
629. Aggressive Lymphomas, Immunotherapy including Bispecific Antibodies: Poster III
Presentation ID 5525:
Presenter: Rahul Shah, M.D.
631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster III
Presentation ID 5526:
Presenter:
Presentation ID 5542:
Presenter:
632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster III
Presentation ID 5550:
Presenter:
Presentation ID 5564:
Presenter:
Presentation ID 5565:
Presenter:
634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster III
Presentation ID 5602:
Presenter:
636. Myelodysplastic Syndromes: Basic and Translational: Poster III
Presentation ID 5613:
Presenter:
637. Myelodysplastic Syndromes: Clinical and Epidemiological: Poster III
Presentation ID 5641:
Presenter:
Presentation ID 5644:
Presenter:
Presentation ID 5645:
Presenter: Roberta Santos Azevedo. M.D.
Presentation ID 5647:
Presenter:
642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster III
Presentation ID 5685:
Presenter: Alexandra Lovell, Pharm.D.
Presentation ID 5687:
Presenter:
651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster III
Presentation ID 5734:
Presenter: Upasana Ray, Ph.D.
653. Multiple Myeloma: Clinical and Epidemiological: Poster III
Presentation ID 5769:
Presenter:
654. Multiple Myeloma: Pharmacologic Therapies: Poster III
Presentation ID 5834:
Presenter:
704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster III
Presentation ID 5921:
Presenter:
Presentation ID 5938:
Presenter:
Presentation ID 5951:
Presenter: Mark Forsberg, M.D.
721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Poster III
Presentation ID 5994:
Presenter:
Presentation ID 5996:
Presenter:
722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Poster III
Presentation ID 6022:
Presenter:
723. Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence: Poster III
Presentation ID 6058:
Presenter:
901. Health Services and Quality Improvement: Non-Malignant Conditions Excluding Hemoglobinopathies: Poster III
Presentation ID 6163:
Presenter:
Presentation ID 6174:
Presenter: Reeja Raj, D.O.
906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Poster III
Presentation ID 6299:
Presenter: Lohitha Dhulipalla, M.D.
Presentation ID 6319:
Presenter: Rahul Shah, M.D.
908. Outcomes Research: Myeloid Malignancies: Poster III
Presentation ID 6391:
Presenter:
Presentation ID 6407:
Presenter:
ASH Poster Walks
Sunday, Dec. 7
8每9 a.m.
Session ID pw16:
Orange County Convention Center West Halls B3每B4
Chair:
Wednesday, December 10
10每11 a.m.
Session ID pw27:
ASH Virtual Platform
Chair:
Give Now
Your gift will help make a tremendous difference.
Research Areas
Find out about the four types of research taking place at MD Anderson.
Subscribe
Get the latest information on our cancer breakthroughs.?